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Background: Amrubicin, a new anthracycline agent, has shown
high activity for small-cell lung cancer (SCLC) with acceptable
toxicities in previous studies. However, a combination regimen of
platinum and amrubicin for elderly patients has not been reported. In
this phase I study, the dose-limiting toxicity (DLT), the maximal
tolerable dose (MTD), and the antitumor activity of a combination of
amrubicin and carboplatin in elderly patients with SCLC were
evaluated.
Patients and Methods: Previously untreated elderly patients (70
years old) with SCLC were enrolled in this study. Amrubicin was
administered from day 1 to day 3, and carboplatin was administered
on day 1 intravenously. The treatment was repeated every 3 weeks.
Three escalating dose levels of amrubicin (mg/m2)/carboplatin (area
under the curve; AUC) (40/4.0, 40/5.0, and 45/5.0) were initially
planned.
Results: Twelve patients were enrolled. At level 1 (amrubicin 40
mg/m2 and carboplatin AUC 4.0), all three patients experienced
DLTs (grade 4 neutropenia 4 days, thrombocytopenia 20,000/
mm3, or grade 3 diarrhea), and this dose level was determined to be
the MTD. At the reduced dose of level 0 (amrubicin 35 mg/m2 and
carboplatin AUC 4.0), although DLTs were observed in three of the
nine patients, they were considered to be clinically not severe and
could be managed. Non-hematological toxicities were mild or mod-
erate and reversible. The objective response rate was 83%, and the
median survival time was 12.7 months.
Conclusions: The MTD of this combination was amrubicin 40
mg/m2 and carboplatin AUC 4.0, and the recommended dose for a
phase II trial is a combination of amrubicin 35 mg/m2 and carbo-
platin AUC 4.0. We are now conducting a multicenter phase II trial
of this regimen to determine the activity of this combination for
elderly patients with SCLC.
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Lung cancer is a leading cause of cancer death in manycountries,1,2 and small-cell lung cancer (SCLC) accounts
for 15% to 25% of all lung cancer cases. More than 50% of
patients newly diagnosed with SCLC are older than 70 years,
and the number of elderly patients is expected to increase
because the geriatric population is also rapidly growing.3–5
Physicians tend to believe that aged patients often have poor
tolerance for chemotherapy (especially cisplatin-containing
regimens). As a result, although standard chemotherapies for
SCLC including both limited disease (LD) and extensive
disease (ED) have been established, there is the potential to
undertreat elderly patients because of the fear of excessive
toxicity.6 Thus, it is important to establish a feasible treatment
regimen for elderly patients with SCLC.
Amrubicin is a new anthracycline agent that yielded an
extremely high response rate of 79% and median survival
time of 11 months in ED-SCLC, which was comparable to
the results of a combined regimen of cisplatin and etoposide
for ED-SCLC, and showed acceptable toxicities.7 The rec-
ommended dose of amrubicin alone is 45 mg/m2, and a phase
II study of amrubicin (40 mg/m2) combined with cisplatin (60
mg/m2) has also shown promising activity for SCLC.8 How-
ever, this combination study enrolled only patients younger
than 75 years, and included patients mostly younger than 70
years old.
Carboplatin is widely used for elderly patients with
lung cancer instead of cisplatin because of its mild, non-
hematological toxicity. The combination of carboplatin and
etoposide has shown moderate activity for elderly patients
with SCLC.9
We therefore considered that a combination of amru-
bicin and carboplatin could be feasible and effective for
elderly patients with SCLC and planned a phase I study of
this combination regimen. A primary objective of this study
was to determine the dose-limiting toxicity (DLT) and the
maximal tolerable dose (MTD) of the combination. The
secondary objectives included evaluation of the response rate
and survival and determination of the recommended dose
(RD) for a subsequent phase II study.
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METHODS
Patient Selection
Patients aged 70 years or older with histologically
confirmed SCLC who had never received chemotherapy or
radiotherapy were enrolled in this study. Other eligibility
criteria included Eastern Cooperative Oncology Group
(ECOG) performance status (PS) 0 or 1, and estimated life
expectancy 12 weeks. Laboratory requirements included
hemoglobin 9 g/dL, white blood cell count 4,000/mm3,
absolute neutrophil count 2000/mm3, platelets 100,000/
mm3, serum bilirubin 1.5 times the institutional upper limit
of normal, aspartate transaminase (AST) and alanine amino-
transferase (ALT) 100 international unit (IU)/L, and creat-
inine clearance 40 mL/min. Patients with symptomatic
brain metastasis or severe comorbidity were excluded. Each
hospital’s institutional review board approved the study, and
written informed consent was obtained from all enrolled
patients.
Clinical Study Design
Amrubicin was diluted in 20 mL of normal saline and
administered as a bolus during a drip infusion of normal
saline on days 1, 2, and 3 of each treatment cycle. Carboplatin
was diluted in 250 mL of 5% glucose solution and adminis-
tered after amrubicin by 1-hour intravenous infusion on day
1. The treatment schedule was repeated on a 21-day cycle.
Premedication with corticosteroid and antiemetic 5-HT3 an-
tagonist was recommended. No prophylactic granulocyte col-
ony-stimulating factor or prophylactic antibiotic support was
planned. Granulocyte colony-stimulating factor was permit-
ted to start when the neutrophil count decreased to lower than
1000/mm3 or febrile neutropenia was observed. This limita-
tion was applied only at the first cycle. All patients received
the treatment up to four cycles unless their disease pro-
gressed, unacceptable toxicity occurred, the patient refused
further treatment, or the physician decided to discontinue the
treatment.
The planned dose levels are shown in Table 1. Initially,
three patients were treated at dose level 1, and no intra-patient
dose escalation was allowed. When no DLT was noted by day
21, a subsequent dose escalation proceeded at one dose-level
increments, using three patient cohorts. When one or two
patients showed DLT, three additional patients were added,
for a total of six patients. When all three patients showed
DLT, the patient accrual continued at the previous lower dose
level. The MTD was defined as the lowest dose level at which
more than three patients experienced DLT. If all three pa-
tients experienced a DLT at level 1, a dose reduction to level
0 was planned. DLT was defined as: (1)  grade 3 non-
hematological toxicities except nausea/vomiting; (2) throm-
bocytopenia 20,000/mm3; (3) grade 4 neutropenia lasting
4 days; (4) febrile neutropenia during the first cycle. Tox-
icities were assessed according to National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 2.0.
Second-line chemotherapy or other treatments after this
study were not prohibited by the protocol. One patient with
stage IIIA and two patients with stage IIIB disease were
sequentially treated with thoracic radiotherapy after this
study.
Treatment Assessment
Baseline assessment included a physical examination,
complete blood counts with differential and platelet count,
hepatic and renal functions tests, urine analysis, 12-lead
electrocardiogram, and chest radiograph. Measurement of
visible and palpable tumors was performed at baseline by
chest radiograph, computed tomography (CT) scans, or mag-
netic resonance imaging (MRI) scans (when clinically indi-
cated). During the study, the medical history and results of
physical examination, weight, vital signs, ECOG PS, com-
plete blood counts, and blood chemistry were monitored
weekly, and urinalysis was performed every 3 weeks. Radio-
graphic evaluation (CT, MRI, or chest radiograph) was per-
formed to assess the response to the treatment. Unidirectional
measurements were undertaken using the new World Health
Organization criteria (RECIST criteria). Tumor response as-
sessment was performed at least every two cycles while the
patients were in the study.
RESULTS
Patient Characteristics and Treatment
Administration
Twelve patients were enrolled from February 2003 to
August 2005. The patients’ characteristics are listed in Table
2. A total of 41 treatment cycles were administered with a
median of four cycles per patient (range, one to four cycles).
Three patients were treated at dose level 1 (amrubicin 40
mg/m2 and carboplatin of AUC 4.0), and nine patients re-
ceived the reduced dose of level 0 (amrubicin 35 mg/m2 and
carboplatin AUC 4.0). All patients were assessable for tox-
icity, tumor response, and survival.
Hematological Toxicity
Most of patients experienced  grade 3 myelosuppres-
sion, although serious complications were not observed at
TABLE 1. Planned dose of each level
Amrubicin (mg/m2) Carboplatin (AUC) Enrolled patients
Level
3 45 5.0
2 40 5.0
1a 40 4.0 3
0 35 4.0 9
AUC, area under the curve. aStarting dose.
TABLE 2. Patient characteristics
Enrolled patients 12
Gender Male/female 9/3
Age (yr) Median (range) 74 (71–77)
Performance status 0/1 4/8
Stage IIIA/IIIB/IV 1/3/8
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level 1 or 0 (Table 3). Five patients experienced grade 3
thrombocytopenia, although only one patient at level 1 re-
quired a platelet transfusion. Grade 3 anemia occurred in two
patients, and both patients received a blood transfusion when
the hemoglobin level decreased by 6.8 and 6.5 mg/dL, re-
spectively. One patient at level 0 experienced grade 4 anemia
(hemoglobin level 6.0 mg/dL) in the forth cycle, which was
recovered without blood transfusion. There was no treatment-
related death.
Non-Hematological Toxicities
The common non-hematological adverse events were
fatigue, appetite loss, nausea, and liver dysfunction (AST
and/or ALT elevation), all of which were mild or moderate
and reversible as summarized in Table 3. One patient devel-
oped grade 3 diarrhea that was evaluated as DLT although the
episode improved within a few days. Three patients who
received thoracic radiation after this study have not suffered
from radiation recall phenomenon.
DLT and MTD
Two dose levels were examined in this study. Dose
level 1 (starting dose) was considered to be too toxic because
all three patients experienced DLTs as follows: three experi-
enced grade 4 neutropenia lasting 4 days, one experienced
thrombocytopenia20,000/mL, and one experienced grade 3
diarrhea (Table 3). According to the protocol definition, the
MTD of this regimen was determined to be dose level 1.
At dose level 0, two cases of DLTs were also observed
in the first three patients, both of which were related to
neutropenia. One experienced grade 4 neutropenia lasting 4
days, and the other developed febrile neutropenia with grade
4 neutropenia lasting 3 days. Because these cases were
considered to be clinically not severe and could be managed,
we decided to add six more patients at level 0 to evaluate the
safety. Among those six patients, only one experienced DLT
(grade 4 neutropenia lasting 4 days) that was not also clini-
cally severe. Thus, we decided that the RD for the phase II
study of this regimen would be dose level 0.
Antitumor Activity
Major antitumor activity was observed in 10 patients
(83%). One patient in level 0 had complete response (Table
4). At the survival assessment in late February 2006, seven
patients were still alive, and the median survival time of
patients in this study was 12.7 months.
DISCUSSION
A limited number of prospective studies for elderly
patients with SCLC have been reported. Because most of
those studies consisted of heterogeneous populations, such as
elderly patients with good PS and younger patients with poor
PS, their treatment outcomes varied.10 Elderly patients with
good PS and normal organ functions tend to be treated with
regimens similar to those of younger patients, but some
recent reports suggested that even with good PS and normal
organ functions, elderly patients had a greater risk of severe
toxicities than younger patients.11–13 Although the carboplatin
and etoposide combination seems to be the most appropriate
chemotherapy among elderly patients with SCLC, the re-
sponse and survival rates of this regimen are not comparable
to those of the standard chemotherapy for younger patients
with SCLC. In this context, a prospective study to determine
an optimal and effective regimen for elderly patients with
SCLC who are in good general condition is still warranted.
The principle toxicity of the amrubicin and carboplatin
combination in this study was myelosuppression, thereby
showing similar profile to the results of previous studies of
amrubicin alone.7 Even at dose level 1 (amrubicin 40 mg/m2
TABLE 3. Hematological and non-hematological toxicities
Hematological toxicities (NCI-CTC grade) Non-hematological toxicities (NCI-CTC grade)
Patient No. Gender Age Neut Hb Plt FN < Grade 2 > Grade 3 DLT
Level 1
1 Male 76 4a 1 3 0 Appetite loss (1), fatigue (1), AST/ALT (1) None Yes
2 Male 77 4a 3b 3b 0 Appetite loss (1), nausea (1), alopecia (1),
fatigue (1), dizziness (1)
None Yes
3 Male 72 4a 1 1 0 Nausea (1), fatigue (1), AST/ALT (1) diarrhea (3) Yes
Level 0
4 Male 77 4a 3b 3 0 Appetite loss (2), nausea (2), vomiting (2) None Yes
5 Female 72 4 2 1 0 Alopecia (1), AST/ALT (1) None No
6 Female 71 4 1 0 3 Fever (2), alopecia (2), appetite loss (1) None Yes
7 Male 72 3 2 3 0 Infection (2) None No
8 Male 74 4 4 2 0 None None No
9 Male 73 2 1 0 0 Fatigue (2) None No
10 Female 75 4 2 2 0 Nausea (2) None No
11 Male 77 4a 2 3 3 None None Yes
12 Male 73 4 2 3 0 None None No
Neut, neutropenia; Hb, anemia; Plt, thrombocytopenia; FN, febrile neutropenia; DLT, dose-limiting toxicity. aGrade 4 neutropenia lasting4 days. bPerformed blood transfusion.
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and carboplatin AUC 4.0), all three patients developed grade
4 neutropenia lasting 4 days, and two of three patients
developed grade 3 thrombocytopenia during their first cycle.
Although these toxicities were transient and did not cause
severe complications, dose level 1 was evaluated as too toxic
and not suitable for the elderly patients.
Dose reduction to level 0 (amrubicin 35 mg/m2 and
carboplatin AUC 4.0) could decrease the degrees of the
toxicities. Although three of nine patients experienced DLTs
such as grade 4 neutropenia lasting 4 days and febrile neu-
tropenia with grade 3 neutropenia, these episodes were tran-
sient and subsided immediately. Thus, we decided that dose
level 0 could be managed and recommended this dose for a
subsequent multicenter phase II trial. Non-hematological tox-
icities were mostly mild to moderate in this treatment, as
expected. Although one case of grade 3 diarrhea was ob-
served and evaluated as DLT, that episode improved within a
few days and was possibly related to the inappropriate taking
of purgatives.
Unlike other anthracyclines, myocardial toxicity has
not been reported in previous clinical trials and post-market-
ing surveillance of amrubicin. In this phase I trial, we did not
observe any change of myocardial function by echocardiog-
raphy examined pre- and post-chemotherapy. However, be-
cause careful attention should be paid to myocardial toxicities
in patients treated with accumulating doses of an anthracy-
cline agent, we excluded patients with impaired cardiac
function at the enrollment of the subsequent phase II study.
Regarding the effectiveness of this regimen, the objec-
tive response rate of 83% and median survival of 12.7 months
was quite promising, although the number of patients was
quite small. Okamoto et al.9 reported a phase II study of
carboplatin (AUC 5.0 on day 1) and etoposide (100 mg/m2 on
days 1, 2, and 3) for elderly patients with SCLC, which
consisted of 16 LD and 20 ED patients. Frequent adverse
events  grade 3 were hematological, such as neutropenia
(91%), thrombocytopenia (53%), or anemia (35%). The over-
all response rate was 75% and the median survival time was
10.8 months. Although it is not appropriate to compare these
different regimens, the profiles of adverse events and the
activity of carboplatin and etoposide were very similar to
those of carboplatin and amrubicin in our study. In this
context, we consider that the amrubicin and carboplatin
combination is a potential alternative regimen to the conven-
tional regimen for elderly patients with SCLC.
CONCLUSION
In this phase I trial, the MTD of this combination was
amrubicin 40 mg/m2 and carboplatin AUC 4.0. DLTs were
bone marrow suppression, including febrile neutropenia and
thrombocytopenia, and diarrhea. The RD for the phase II trial
is a combination of amrubicin 35 mg/m2 and carboplatin
AUC 4.0. We are now conducting a multicenter phase II trial
of this regimen. Figure 1.
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